SCHEMBL10183192

SCHEMBL10183192

Cn1c(N)nc2cnc(C(C)(C)C)cc21

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 2/20 0.34
NTRK1 P04629 1/20 0.34
LTK P29376 1/20 0.34
TYRO3 Q06418 1/20 0.34
NTRK2 Q16620 1/20 0.34
KDM4E B2RXH2 2/20 0.33
DAPK3 O43293 1/20 0.33
CSNK1A1 P48729 1/20 0.33
LIMK1 P53667 1/20 0.33
TNK2 Q07912 1/20 0.33
ROCK1 Q13464 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
PRMT5 O14744 1/20 0.33
POLB P06746 1/20 0.32
HSD17B10 Q99714 1/20 0.31
TLR8 Q9NR97 2/20 0.31
PIK3CB P42338 1/20 0.30
MMP12 P39900 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14866990 0.81 ACSS2 (0.33)
SCHEMBL10183193 0.81 KDM4E (0.46) KDM4EHSD17B10
SCHEMBL13275348 0.77 UHRF1 (0.39) CLK4NTRK1LTKTYRO3NTRK2
SCHEMBL1585416 0.76 MMP12 (0.37) CLK4NTRK1LTKTYRO3NTRK2
SCHEMBL9968084 0.74 KDM4E (0.32) KDM4E
SCHEMBL10235420 0.73 POLB (0.35) CLK4NTRK1LTKTYRO3NTRK2
SCHEMBL21230341 0.72 CA2 (0.37) CLK4NTRK1LTKTYRO3NTRK2
SCHEMBL23478584 0.71 SCN10A (0.41) CLK4NTRK1LTKTYRO3NTRK2
SCHEMBL10184750 0.71 CLK4 (0.40) CLK4NTRK1LTKTYRO3NTRK2
SCHEMBL10183099 0.70 DYRK1A (0.38) KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF CLK4 1419/4885NTRK1 932/4885LTK 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.